Currently set to Index
Currently set to Follow

It is possibly the most pertinent question regarding the ESYSTA System: Is it beneficial? Or in more technical terms: Does using ESYSTA have a medical benefit for diabetes patients and if so, what is that benefit? These questions are not only at the forefront for patients, doctors and health insurance providers, Emperra, as the developer of the ESYSTA System, also wanted a straight answer. Therefore, the S-T-A-R-T study (Systematic Trial with Analysis of Results in Telemedicine) was launched.

The S-T-A-R-T study in short

This observational study was developed in cooperation with a health insurance provider and the Technical University Dresden. In total, 215 type 1 and type 2 diabetes patients used the ESYSTA System for min. 12 months. In the process, the development of the relevant blood values was collected. In addition, hypoglycaemia rates, use of insulin, health-related quality of life and user-satisfaction were also analysed.

The most important results of the S-T-A-R-T study

  • Among type 2 diabetes patients: reduction of the HbA1c value by on average 2 %
  • All patients: reduction of the HbA1c value by on average 0.9 %
  • The higher the original HbA1c value, the greater the decrease at the end of the trial
  • Despite a decreased HbA1c value, the hypoglycaemia value did not increase
  • Insulin use and blood pressure values also trended toward decreasing values (a longer trial period would have been more revealing for these aspects)
  • Improvement of quality of life, in particular due to decreased physical pain and fewer emotional problems
  • Heightened motivation and improved self-management among the patients
  • Improved communication between doctors and patients
  • A total of 93 % of doctors and 84 % of patients would recommend the ESYSTA System

Conclusion from the S-T-A-R- -study

The ESYSTA System verifiably improves patients’ HbA1c value, motivation and quality of life as well as the essential communication between doctors and patients.

For anyone who would like to find out more: The whitepaper fo the S-T-A-R-T study

The whitepaper is available for download. If you are interested in reading the entire study, please contact Emperra to receive a copy.

And how does this benefit society? Study on the economic benefit of the ESYSTA System

Improving the health and quality of life of diabetes patients is a big win for humanity. But the solidarity-based healthcare system also benefits greatly. A long-term decrease of diabetes patients’ HbA1c value entails considerable savings potentials. To actually quantify this benefit, the Niederrhein University of Applied Sciences and the Berlin Institute of Health conducted and published a health-economic analysis based on the S-T-A-R-T study.

Increasing numbers of diabetes cases result in increasing treatment costs

As discussed in our article on the “diabetes epidemic“, the number of diabetes cases is constantly increasing. This applies in particular to type 2 diabetes. More and more people are developing this disease, and the patients are becoming younger and younger. Due to the growing number of patients, the costs for treatments are also increasing (both for diabetes mellitus itself as well as for the numerous and often times severe secondary diseases). In 2008, these costs amounted to 6.34 billion euros, in 2015[1] this figure had already increased to 7.31 billion euros.

Proven savings potentials thanks to the ESYSTA System

  • Maximum savings potential if the HbA1c value of patients between the ages of 41 and 95 is sustainably reduced from 9.0 to 7.0 %: 1,088.07 euros.[2]
  • Maximum savings potential if the HbA1c value of patients between the ages of 41 and 95 is sustainably reduced from 9.6 to 6.6 %: 1,147.51 euros.[3]
  • The greatest savings potential occurs if the HbA1c value of patients between the ages of 41 and 61 is sustainably reduced from 8.0 to 6.0 %: 1,238.85 euros.[4]

Why the real savings potentials are probably even higher:

  • It was not possible to consider all secondary diabetes diseases, and therefore not all real costs, in the analysis. The reason: lacking data. Therefore, the true savings potentials are probably higher than those calculated so far.
  • The health-economic analysis portrays the perspective of the statutory health insurance providers. Therefore, national economic costs, such as e.g. reductions in earning capacities, are not taken into account.

For anyone who would like to find out more: abstract and link to purchase the study

The summary can be accessed via this link. If you are interested in reading the entire study, please contact Emperra to receive a copy.

 

Conclusion: ESYSTA is verifiably an asset for patients and for society

 

Do you also want to benefit from the ESYSTA System?

Then invest in Emperra today – the developers of the ESYSTA System – on the digital venture capital platform Aescuvest.

______________________

[1] https://www-genesis.destatis.de/genesis/online?operation=previous&levelindex=1&step=1&titel=Ergebnis&levelid=1602762032090&acceptscookies=false#abreadcrumb

[2] per year and patient

[3] per year and patient

[4] per year and patient